| AJCC 7 | American Joint Committee on Cancer, 7th edition |
| CanSaRCC | Canadian Sarcoma Research and Clinical Collaboration |
| CI | Confidence interval |
| CNS | Central nervous system |
| CT | Chemotherapy |
| DMFS | Distant metastasis-free survival |
| DRFS | Distant recurrence-free survival |
| DSS | Disease-specific survival |
| FNCLCC | Fédération nationale des centres de lutte contre le cancer |
| G1 | Grade 1 |
| G2 | Grade 2 |
| G3 | Grade 3 |
| Gy | Gray |
| HR | Hazard ratio |
| I2 | I-squared statistic for heterogeneity |
| IQR | Interquartile range |
| LRFS | Local recurrence-free survival |
| MFS | Metastasis-free survival |
| MFH | Malignant fibrous histiocytoma |
| MPNST | Malignant peripheral nerve sheath tumor |
| N/A | Not applicable |
| NOS | Newcastle–Ottawa Scale |
| OS | Overall survival |
| PLD | Pegylated liposomal doxorubicin |
| PRISMA | Preferred Reporting Items for Systematic Reviews and Meta-Analyses |
| PROSPERO | International Prospective Register of Systematic Reviews |
| PRS | Post-radiation sarcoma |
| R0 | Microscopically margin-negative resection |
| R1 | Microscopically margin-positive resection |
| R2 | Macroscopically incomplete resection/macroscopic residual disease |
| RFS | Relapse-free survival |
| RIS | Radiation-induced sarcoma |
| RT | Radiotherapy |
| SD | Standard deviation |
| UPS | Undifferentiated pleomorphic sarcoma |